News

Bioethanol as a Biofuel and an Alcoholic Drink

Green Science Alliance Developed an Effective Method for Making Bioethanol from Plants, Wood, Wood Waste, Paper Waste and Food Waste. The Challenge Now is to Use Bioethanol as a Biofuel and an Alcoholic Drink

Global warming is a serious problem, mainly because of the increase in greenhouse gases such as methane and carbon oxide (CO2), as well as society's dependence on petroleum products. Large amounts of money have been spent to research and develop new kinds of energy sources instead of petroleum-based fuel.

Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection

Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd. is voluntarily recalling three lots of Vecuronium Bromide for Injection, 10 mg (lyophilized powder), and one lot of Vecuronium Bromide for Injection, 20 mg (lyophilized powder) to the hospital level.

Lipofilling, Expanded Stem Cells Are a Valuable Alternative to Breast Implants

Easy availability of donor tissue, absence of scars, short recovery times: several advantages have made lipofilling a promising technique for breast augmentation, asymmetry correction and reconstruction, but fat resorption can severely limit results.

Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl

Adial Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced plans to expand activities around the Company’s lead asset, AD04, beyond alcohol use disorder (AUD), to now include its potential use in patients with opioid use disorder.

Hycor receives FDA 510(k) Clearance for NOVEOS™

Hycor Biomedical Receives FDA 510(k) Clearance for NOVEOS™, Its Modern Allergy Testing Instrument

Hycor Biomedical, a leading manufacturer of in vitro diagnostic products for allergy and autoimmune testing, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its new allergy testing system, NOVEOS.

QPS: Phase I Clinical Trial Capabilities

QPS Expands U.S.-Based Phase I Clinical Trial Capabilities to Support the Growing Needs of Its Pharmaceutical, Biotechnology and CRO Partners

QPS, a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development, and expanding its U.S.-based Phase I clinical trial capabilities to support the growing needs of its pharmaceutical, biotechnology and CRO partners.

California research team publishes promising results from peptide based universal cancer vaccine

A team of researchers from the Dr. Rath Research Institute in California has developed a cancer vaccine effective in reducing tumor growth.

Baxter Highlights Clinical Data at ASN: Kidney Week Showing How New Technologies Are Advancing Dialysis Care across Modalities

Baxter International Inc. (NYSE:BAX), a global innovator in renal care, highlighted findings from HDx (expanded hemodialysis) and peritoneal dialysis (PD) studies presented at the American Society of Nephrology (ASN): Kidney Week, Oct. 23-28, showing how novel renal care technologies are positively impacting patient care and clinic efficiency.

At the Forefront of Ovarian Cancer Treatment - Sheba Medical Center Offers TIL Trials

In January 2018, doctors at the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center implemented a breakthrough protocol for ovarian cancer.

Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports no Challenges to European Patent

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the strengthening of its intellectual property (IP) portfolio, as it has successfully passed the patent opposition period in Europe..

Pharmaceutical Industry News